PDF(Pubmed)
Abstract：
UNASSIGNED: Multiple myeloma (MM) is a malignant tumor originating from plasma cells in the bone marrow. The existing treatment methods can prolong the survival time of patients, but they still face the problems of myeloma relapse and refractory disease. Chimeric antigen receptor (CAR)-T cell therapy is a new cellular immunotherapy that can target and recognize antigens and kill tumor cells but the efficacy and safety data varied in different studies. We performed this systematic review and meta-analysis to understand its efficacy and safety.
UNASSIGNED: Literature published from January 2015 to November 2021 was obtained by searching the keywords \"CAR-T\", \"CAR-T Cell\", and \"Multiple Myeloma\" by computer using the Embase, PubMed, Web of Science, and Cochrane library databases according to the PICOS (Participants, Interventions, Comparisons, Outcomes, Study type) criteria. The quality of the literature was assessed by the Joanna Briggs Institute (JBI) Critical Appraisal Tool for prevalence studies. The complete response rate, the incidence of cytokine release syndrome (CRS) above grade 3, and the overall incidence of adverse reactions were used as the outcome indicators. The pooled rates were performed and analyzed using the R language toolkit.
UNASSIGNED: A total of 10 studies including 353 study cases were included. Meta-analysis showed that the pooled complete response rate of CAR-T therapy in the treatment of MM was 0.55, 95% confidence interval (CI): (0.50, 0.60), the pooled incidence of CRS was 0.55, 95% CI: (0.50, 0.60), and the pooled incidence of serious adverse reactions was 0.92, 95% CI: (0.88, 0.95). Subgroup analysis was performed based on antigen types or costimulatory molecules, and there was no significant difference in the efficacy of CAR-T and the incidence of CRS between the two subgroups (P>0.05).
UNASSIGNED: As a new immunotherapy strategy with great potential, CAR-T has a significant effect in the treatment of MM, but its safety needs to be further improved. The types of costimulatory molecules and CAR-T antigens can affect its efficacy and safety.
UNASSIGNED: Literature published from January 2015 to November 2021 was obtained by searching the keywords \"CAR-T\", \"CAR-T Cell\", and \"Multiple Myeloma\" by computer using the Embase, PubMed, Web of Science, and Cochrane library databases according to the PICOS (Participants, Interventions, Comparisons, Outcomes, Study type) criteria. The quality of the literature was assessed by the Joanna Briggs Institute (JBI) Critical Appraisal Tool for prevalence studies. The complete response rate, the incidence of cytokine release syndrome (CRS) above grade 3, and the overall incidence of adverse reactions were used as the outcome indicators. The pooled rates were performed and analyzed using the R language toolkit.
UNASSIGNED: A total of 10 studies including 353 study cases were included. Meta-analysis showed that the pooled complete response rate of CAR-T therapy in the treatment of MM was 0.55, 95% confidence interval (CI): (0.50, 0.60), the pooled incidence of CRS was 0.55, 95% CI: (0.50, 0.60), and the pooled incidence of serious adverse reactions was 0.92, 95% CI: (0.88, 0.95). Subgroup analysis was performed based on antigen types or costimulatory molecules, and there was no significant difference in the efficacy of CAR-T and the incidence of CRS between the two subgroups (P>0.05).
UNASSIGNED: As a new immunotherapy strategy with great potential, CAR-T has a significant effect in the treatment of MM, but its safety needs to be further improved. The types of costimulatory molecules and CAR-T antigens can affect its efficacy and safety.
摘要：
未经证实：多发性骨髓瘤（MM）是起源于骨髓中浆细胞的恶性肿瘤。现有的治疗方法可以延长患者的生存时间,但是他们仍然面临骨髓瘤复发和难治性疾病的问题。嵌合抗原受体（CAR）-T细胞疗法是一种新的细胞免疫疗法，可以靶向和识别抗原并杀死肿瘤细胞，但疗效和安全性数据在不同的研究中有所不同。我们进行了系统评价和荟萃分析，以了解其有效性和安全性。
UNASSIGNED：2015年1月至2021年11月发布的文献是通过搜索关键字“CAR-T”获得的，\"CAR-T细胞\",和“多发性骨髓瘤”通过计算机使用Embase，PubMed,WebofScience,和根据PICOS的Cochrane图书馆数据库(参与者，干预措施,比较,结果，研究类型)标准。文献的质量由JoannaBriggs研究所（JBI）用于患病率研究的关键评估工具进行评估。完整的响应率，将3级以上细胞因子释放综合征(CRS)的发生率和不良反应的总发生率作为结局指标.使用R语言工具包执行和分析合并率。
UNASSIGNED：共纳入10项研究，包括353例研究病例。Meta分析显示CAR-T治疗MM的合并完全缓解率为0.55,95%置信区间(CI):(0.50,0.60),CRS的合并发生率为0.55，95%CI：(0.50，0.60)，严重不良反应的合并发生率为0.92,95%CI:(0.88,0.95).根据抗原类型或共刺激分子进行亚组分析，2个亚组CAR-T疗效及CRS发生率差异无统计学意义(P>0.05)。
UNASSIGNED：作为一种具有巨大潜力的新型免疫治疗策略，CAR-T在MM的治疗中具有显著的疗效,但其安全性有待进一步提高。共刺激分子和CAR-T抗原的类型会影响其功效和安全性。
UNASSIGNED：2015年1月至2021年11月发布的文献是通过搜索关键字“CAR-T”获得的，\"CAR-T细胞\",和“多发性骨髓瘤”通过计算机使用Embase，PubMed,WebofScience,和根据PICOS的Cochrane图书馆数据库(参与者，干预措施,比较,结果，研究类型)标准。文献的质量由JoannaBriggs研究所（JBI）用于患病率研究的关键评估工具进行评估。完整的响应率，将3级以上细胞因子释放综合征(CRS)的发生率和不良反应的总发生率作为结局指标.使用R语言工具包执行和分析合并率。
UNASSIGNED：共纳入10项研究，包括353例研究病例。Meta分析显示CAR-T治疗MM的合并完全缓解率为0.55,95%置信区间(CI):(0.50,0.60),CRS的合并发生率为0.55，95%CI：(0.50，0.60)，严重不良反应的合并发生率为0.92,95%CI:(0.88,0.95).根据抗原类型或共刺激分子进行亚组分析，2个亚组CAR-T疗效及CRS发生率差异无统计学意义(P>0.05)。
UNASSIGNED：作为一种具有巨大潜力的新型免疫治疗策略，CAR-T在MM的治疗中具有显著的疗效,但其安全性有待进一步提高。共刺激分子和CAR-T抗原的类型会影响其功效和安全性。
